The estimated Net Worth of Salvatore Privitera is at least 6.56 百万$ dollars as of 30 May 2024. Mr. Privitera owns over 5,000 units of Atricure Inc stock worth over 2,778,501$ and over the last 19 years he sold ATRC stock worth over 2,496,476$. In addition, he makes 1,289,980$ as Chief Technology Officer at Atricure Inc.
Sign up
Mr. Privitera ATRC stock SEC Form 4 insiders trading
Salvatore has made over 10 trades of the Atricure Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ATRC stock worth 111,250$ on 30 May 2024.
The largest trade he's ever made was selling 10,654 units of Atricure Inc stock on 17 December 2020 worth over 546,870$. On average, Salvatore trades about 1,462 units every 119 days since 2005. As of 30 May 2024 he still owns at least 103,290 units of Atricure Inc stock.
You can see the complete history of Mr. Privitera stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Salvatore Privitera biography
Salvatore Privitera serves as Chief Technology Officer of the Company. Salvatore Privitera, J.D. has served as our Chief Technical Officer since January 2020 having previously served as our Chief Technology Officer since July 2017. Prior to joining AtriCure, Mr. Privitera served as Vice President of Research and Development at Bard Medical (“BMD”), a division of C.R. Bard, where he helped grow BMD to over $1 billion in global revenue. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Prior to his role at BMD, Mr. Privitera worked for AtriCure as the Vice President of Engineering and Product Development for nine years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator® Synergy™ Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles for over twelve years. Mr. Privitera received his B.S. from the University of Buffalo, his M.B.A. from Xavier University and his J.D. from Northern Kentucky University.
What is the salary of Salvatore Privitera?
As the Chief Technology Officer of Atricure Inc, the total compensation of Salvatore Privitera at Atricure Inc is 1,289,980$. There are 2 executives at Atricure Inc getting paid more, with Michael Carrel having the highest compensation of 5,829,780$.
How old is Salvatore Privitera?
Salvatore Privitera is 53, he's been the Chief Technology Officer of Atricure Inc since 2017. There are 9 older and 3 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
What's Salvatore Privitera's mailing address?
Salvatore's mailing address filed with the SEC is 7555, Innovation Way, Innovation Business Center, Mason, Warren County, Ohio, 45040, United States.
Insiders trading at Atricure Inc
Over the last 19 years, insiders at Atricure Inc have traded over 52,789,242$ worth of Atricure Inc stock and bought 666,621 units worth 5,937,195$ . The most active insiders traders include Scott William Drake、Group I, Llc Donoghue Danie...、Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of 548,410$. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth 84,245$.
What does Atricure Inc do?
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
What does Atricure Inc's logo look like?
Complete history of Mr. Privitera stock trades at Atricure Inc
Atricure Inc executives and stock owners
Atricure Inc executives and other stock owners filed with the SEC include:
-
Michael Carrel,
President, Chief Executive Officer, Director -
Douglas Seith,
Chief Operating Officer -
Salvatore Privitera,
Chief Technology Officer -
Justin Noznesky,
Senior Vice President, Marketing and Business Development -
Scott Drake,
Independent Chairman of the Board -
Sven Wehrwein,
Independent Director -
Mark Lanning,
Independent Director -
B. Kristine Johnson,
Independent Director -
Robert White,
Independent Director -
Regina Groves,
Independent Director -
Mark Collar,
Independent Director -
Karen Prange,
Independent Director -
Daniel Florin,
Independent Director -
Angela Wirick,
Chief Financial Officer -
Shlomo Nachman,
Director -
Karen P Robards,
Director -
Elizabeth D Krell,
Director -
Richard M Johnston,
Director -
Michael D Hooven,
Director -
Andrew L Lux,
V.P. & Chief Operating Officer -
Group I, Llc Murphy Michael...,
-
M. Andrew Wade,
CFO -
Tonya Austin,
Chief Human Resources Officer -
Deborah L Morley,
VP Clinical Affairs -
Lee R Wrubel,
Director -
Maureen Shaffer,
Vice President Marketing -
Jon A Sherman,
VP Product Development -
Elsa Chi Abruzzo,
VP; Regulatory&ClinicalAffairs -
Alan L Kaganov,
Director -
Richard S Walsh,
Vice President; Sales -
Management Group Viii L L C...,
-
Management Group Viii L L C...,
-
Stephen S Cambridge,
Vice President; Sales -
Management Group Viii L L C...,
-
Thomas J Etergino,
Vice President and CFO -
Norman R Weldon,
Director -
Patricia J Kennedy,
VP, GM, International -
James L Lucky,
VP; QA & Healthcare Compliance -
Management Group Viii L L C...,
-
David J Drachman,
President and CEO -
Richard Mcamden Partners St...,
-
Richard Mcamden Partners St...,
-
Donald C Harrison,
Director -
Group I, Llc Donoghue Danie...,
-
Stewart W Strong,
Vice President US Sales -
Management Group Viii L L C...,
-
Frederick Preiss,
Vice President; Operations -
Julie A Piton,
VP and CFO -
Deborah H Telman,
Director -
Karl S. Dahlquist,
Chief Legal Officer -
Vinayak Doraiswamy,
Chief Scientific Officer -
Maggie Yuen,
Director -
Deborah Lee Yount,
Chief Human Resources Officer